Genetic subtypes of JMML
| I. Somatic PTPN11 mutation |
| • Rapidly fatal without allogeneic HSCT |
| • High probability of relapse |
| • Frequent acquisition of NF1 haploinsufficiency |
| II. Somatic NRAS mutation |
| • Heterogeneous subtype |
| • Rapid progress with high relapse rate after HSCT, typically in older children with high levels of HbF |
| • Indolent course with spontaneous regression, typically in infants or in cases with G12S mutation |
| III. Somatic KRAS mutation |
| • Mostly infants |
| • Frequent association with monosomy 7 |
| • Aggressive at presentation but low risk of relapse after allogeneic HSCT |
| IV. JMML in children with NF1 |
| • Older age at diagnosis |
| • Higher platelet count |
| • Higher percentage of BM blasts |
| • Fatal without allogeneic HSCT |
| V. JMML in children with germline CBL mutation |
| • Loss of CBL heterozygosity in hematopoietic cells |
| • Absence of concomitant mutations |
| • Value of allogeneic HSCT uncertain |
| • Frequent occurrence of mixed chimerism after allogeneic HSCT |
| I. Somatic PTPN11 mutation |
| • Rapidly fatal without allogeneic HSCT |
| • High probability of relapse |
| • Frequent acquisition of NF1 haploinsufficiency |
| II. Somatic NRAS mutation |
| • Heterogeneous subtype |
| • Rapid progress with high relapse rate after HSCT, typically in older children with high levels of HbF |
| • Indolent course with spontaneous regression, typically in infants or in cases with G12S mutation |
| III. Somatic KRAS mutation |
| • Mostly infants |
| • Frequent association with monosomy 7 |
| • Aggressive at presentation but low risk of relapse after allogeneic HSCT |
| IV. JMML in children with NF1 |
| • Older age at diagnosis |
| • Higher platelet count |
| • Higher percentage of BM blasts |
| • Fatal without allogeneic HSCT |
| V. JMML in children with germline CBL mutation |
| • Loss of CBL heterozygosity in hematopoietic cells |
| • Absence of concomitant mutations |
| • Value of allogeneic HSCT uncertain |
| • Frequent occurrence of mixed chimerism after allogeneic HSCT |